Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
Zymeworks (ZYME) said Monday it has completed its acquisition of Theravance Biopharma, adding Yupelr
Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assetsYUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRRZymeworks to retain existing commercial organization supporting YUPELRI hospital promotionThe Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 mill
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
This is the newest page. Registered accounts read further back.